Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
Gain/Loss on Disposition of Assets
Mereo Biopharma Group PLC
Gain/Loss on Disposition of Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gain/Loss on Disposition of Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Immunocore Holdings PLC
NASDAQ:IMCR
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Genus PLC
LSE:GNS
|
Gain/Loss on Disposition of Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Mereo Biopharma Group PLC
Glance View
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).